Changes in the cytokine environment and imbalances between effector CD4+ T cell subsets (e.g., Th17) and FOXP3+ Tregs have been the subject of research in CLL patients [45,46]. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.